Santa Cruz Biotechnology

Santa Cruz Biotechnology

Is this your company? Claim your profile to update info and connect with investors.
Claim profile

Private Company

Funding information not available

Overview

Santa Cruz Biotechnology is a well-established, privately-held provider of critical research tools for the global biomedical research community. The company has built a strong reputation over three decades as a key supplier of antibodies, gene silencing/editing technologies, and basic lab supplies. While its core business is research reagents, it has diversified into animal health through its 'Santa Cruz Animal Health' division. Its extensive product catalog and high citation count underscore its entrenched position in the academic and industrial research markets.

Antibodies

Technology Platform

Integrated provider of research reagents including antibody production, RNAi gene silencing tools, CRISPR/Cas9 gene editing plasmids, and laboratory chemicals/supplies.

Funding History

1
UndisclosedUndisclosed

Opportunities

Sustained growth in global life sciences R&D funding drives demand for research reagents.
Expansion of CRISPR technology adoption and the stable animal health market present adjacent growth avenues.
Leveraging its strong brand and citation legacy to cross-sell new technology products.

Risk Factors

Faces intense competition from larger, diversified life science tools conglomerates.
Reputation is highly sensitive to product quality and validation issues.
Revenue is indirectly tied to cyclical trends in academic and government research funding.

Competitive Landscape

Operates in the highly fragmented and competitive life science reagents market. Competes with global giants like Thermo Fisher Scientific, Abcam, and Merck Millipore on breadth, price, and quality, and with numerous specialized antibody startups on innovation and validation. Its diversification into gene editing tools pits it against dedicated CRISPR companies as well.